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Nonbullous impetigo is a common skin infection in children and is frequently caused by Staphylococcus
aureus. Staphylococcal toxins and especially exfoliative toxin A are known mediators of bullous impetigo in
children. It is not known whether this is also true for nonbullous impetigo. We set out to analyze clonality
among clinical isolates of S. aureus from children with nonbullous impetigo living in a restricted geographical
area in The Netherlands. We investigated whether staphylococcal nasal carriage and the nature of the
staphylococcal strains were associated with the severity and course of impetigo. Bacterial isolates were
obtained from the noses and wounds of children suffering from impetigo. Strains were genetically characterized
by pulsed-field gel electrophoresis-mediated typing and binary typing, which was also used to assess toxin gene
content. In addition, a detailed clinical questionnaire was filled in by each of the participating patients.
Staphylococcal nasal carriage seems to predispose the patients to the development of impetigo, and 34% of
infections diagnosed in the Rotterdam area are caused by one clonal type of S. aureus. The S. aureus strains
harbor the exfoliative toxin B (ETB) gene as a specific virulence factor. In particular, the numbers (P  0.002)
and sizes (P < 0.001) of the lesions were increased in patients infected with an ETB-positive strain. Additional
predictors of disease severity and development could be identified. The presence of a staphylococcal plasmid
encoding multiple antibiotic resistance traits, as detected by binary typing, was associated with a reduction in
the cure rate. Our results recognize that a combination of staphylococcal virulence and resistance genes rather
than a single gene determines the development and course of nonbullous impetigo. The identification of these
microbial genetic markers, which are predictive of the severity and the course of the disease, will facilitate
guided individualized antimicrobial therapy in the future.
Over the past few years the prevalence of streptococci as a
leading cause of impetigo has dropped, whereas Staphylococ-
cus aureus has become the most common causative microbial
pathogen of this prevalent childhood disease (7, 8, 23). S.
aureus is usually encountered as a nasal commensal organism,
but the bacterium may ultimately induce a broad variety of skin
infections. This suggests that staphylococcal carriage predis-
poses an individual to the development of impetigo (14, 25).
Fortunately, the vast majority of these S. aureus strains are still
broadly susceptible to antibiotics, such as fusidic acid and
mupirocin (15, 19, 26).
S. aureus toxins are considered the main effector molecules
in a wide variety of childhood exanthems. The clinical presen-
tation is often due to the effects of various cytokines induced as
a consequence of the infection process, and a variety of disease
mechanisms have been postulated (20, 22). Recently, it was
discovered that staphylococcal exfoliative toxin A (ETA) hy-
drolyzes human desmoglein-1 (1). The destruction of this im-
portant structural skin protein leads to the development of
blisters below the stratum corneum, possibly facilitating bac-
terial proliferation beneath the physical skin barrier. Novel
therapies may be based on these important findings. Conse-
quently, there is a need for versatile laboratory systems en-
abling the direct or indirect detection of toxins and other
virulence factors of clinical isolates of S. aureus (16). However,
one must realize that the mere presence of a certain gene does
not prove its causality in disease. Establishment of the latter
requires detailed clinical studies in addition to molecular di-
agnostics.
We recently performed a double-blind, randomized, place-
bo-controlled trial into the clinical effectiveness of fusidic acid
cream in the treatment of impetigo diagnosed among children
in general practice (15). It showed that fusidic acid cream
treatment significantly accelerated to clinical and bacteriolog-
ical cure of the infection and that the main cause of impetigo
was S. aureus. In the present study we have set out to analyze
the gene and genomic variabilities among the clinical isolates
of S. aureus found at the time of enrollment in the trial (before
treatment), using pulsed-field gel electrophoresis (PFGE)-me-
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diated typing and a novel binary typing (BT) protocol. We
assessed the strains for the presence or absence of toxin-en-
coding genes and investigated whether the virulence gene po-
tential of the staphylococcal strains involved and staphylococ-
cal nasal carriage per se were associated with the severity and
course of the impetigo.
MATERIALS AND METHODS
Bacterial isolates and clinical data collection. Koning et al. (15) described the
isolation of S. aureus strains from children affected by impetigo in the Rotterdam
region of The Netherlands. Swabs for the detection of bacteria were obtained
from the nose, which is the primary ecological niche for S. aureus, and from the
impetigo wound. A trained research nurse obtained all samples at the home visit
for inclusion in the study. Ninety-eight S. aureus strains were analyzed by PFGE
and extended BT (see below). The following clinical parameters were recorded
for all patients (n  98): number of lesions, location of the lesion, surface area
of the lesion, temperature, lymphadenopathy (a patient was defined as positive
once a palpable enlargement of the regional lymph nodes concerned was obvi-
ous), encrustation of the wound, presence of pustules, duration of infection, and
swimming habits. In addition, we recorded the age, sex, ethnicity, quality of living
environment, and kindergarten attendance. We also investigated the relationship
between virulence gene markers of the S. aureus strains and the course of
impetigo, focusing on clinical and bacterial cure 1 week after inclusion in the
study and the start of therapy. Clinical cure was defined as the complete absence
of lesions or the presence of lesions that had become dry without crusts. Bacterial
cure was defined as the absence of S. aureus strains at the lesion. The medical
ethical committee of the Erasmus Medical Center approved the trial protocol,
and informed consent was obtained from the patients and their parents. In case
the patients withdrew from the study protocol, evaluation visits were still carried
out as scheduled.
PFGE analysis. PFGE analysis for S. aureus was performed by established
protocols (27). Electrophoresis was performed in contour-clamped homoge-
neous electric field mappers (Bio-Rad, Veenendaal, The Netherlands) by using
a 20-h program consisting of two switching blocks (10 h for 5 to 15 s and 10 h for
15 to 45 s). The buffer system consisted of 1 TBE (Tris-borate-EDTA),
whereas the temperature was kept constant at 14°C. DNA macrorestriction
fragment-containing blocks were prepared by embedding S. aureus cells and
treating these in situ with lysostaphin (Sigma, Steinheim, Germany), proteinase
K (Sigma), and SmaI (Boehringer, Mannheim, Germany). For size determina-
tion, reference samples containing phage  concatemeric DNA (Bio-Rad) were
included in all gels. After PFGE, the gels were stained with ethidium bromide
and photographed. Interpretation of the banding patterns was performed visu-
ally, and types were assigned as suggested by Tenover et al. (24). In short,
banding patterns differing at less than three band positions were assigned the
same overall type; subtypes were identified by numbering.
Extended BT. BT of the S. aureus strains was performed with the system
developed by Van Leeuwen et al. (28). Twelve strain-selective probes were
immobilized on nylon strips, and reverse hybridization with chemically labeled
staphylococcal DNA was performed. Signals were recorded after staining; and a
1 or 0 binary score was deduced for each of the probes, resulting in a 12-digit 1/0
genotype for each of the strains. This classical approach uses 12 probes for BT
(BIN 1 to 9, 11, 14, and 15). The sequences of these probes are homologous to
unknown regions in the staphylococcal genome (BIN 7), a hypothetical but not
yet identified gene (BIN 2, 5, 8, and 15), the Panton-Valentine leukocidin gene
(BIN 1), a repetitive motif (BIN 3), a pSK41-like multiresistance-encoding plas-
mid (BIN 4), the SLT bacteriophage (BIN 6), the intergenic region between a
tRNA synthetase and an amino acid permease (BIN 9), the 3-hydrocyacyl coen-
zyme A dehydrogenase gene (BIN 11), and the acetyl coenzyme A synthetase
gene (BIN 14). In addition, 11 toxin gene-specific probes were included (18).
These included probes for enterotoxins A, B, C, D, and E; ETA and ETB; toxic
shock syndrome toxin; and hemolysins A, B, and C. All probes were generated
by PCR. The validity of the results obtained by this approach was verified by
including S. aureus strains with a phenotypically determined toxin production
pattern as positive controls (results not shown). The latter strains were obtained
from Max Heck and Wim Wannet (Department of Infectious Disease Epidemi-
ology, State Institute of Public Health and the Environment, Bilthoven, The
Netherlands).
Statistical analyses. For pairwise comparisons, Fisher’s exact tests were per-
formed by using 2-by-2 contingency tables. Two-sided P values were considered
significant once they were 0.05. Numerical analyses were performed by analysis
of variance. The relationship between gene markers and the course of disease
was tested by both univariate analysis and stepwise logistic regression analysis. In
the multivariate analysis, baseline characteristics and treatment modality (fusidic
acid cream or placebo) were included in the analysis.
RESULTS
Genotyping of the bacterial isolates. Ninety-eight S. aureus
isolates from the wounds of as many patients, obtained at their
inclusion visit, were genetically characterized by PFGE and
BT. A novel genotype was defined on the basis of the presence
of three or more band differences in the PFGE pattern, which
was always accompanied by at least two differences in the BT
outcome. Overall, 67 different genotypes could be identified
among these strains. Thirty-nine strains were identified as be-
longing to a single clone, identified by similarities in the PFGE
banding patterns (24). This clone was given the code 8. BT
confirmed the existence of the clonal type as defined by PFGE,
and BT probes BIN 1 to BIN 4 identified most of the genetic
heterogeneity between PFGE type 8 and non-PFGE type 8
(diverse) strains. For all of the binary codes for the clone 8
group (except for those obtained with BIN 2, 3, and 7), excep-
tions to the consensus code were found. This corroborates the
genetic microheterogeneity already detected by PFGE and
confirms that the sequences of the BIN probes originate from
intrinsically unstable regions in the S. aureus genome. We were
unable to document significant geographic clustering of clones
within the Rotterdam area (results not shown).
Toxin gene detection. The hemolysin A to C genes were
present in essentially all of the S. aureus strains isolated during
the Rotterdam impetigo study. The enterotoxin A, D, and E
genes, in contrast, were rare. Furthermore, not all of the clone
8 strains were identical with respect to their toxin gene poten-
tials. When the clonal isolates were compared to the other
(genetically diverse) strains, the presence of ETB and entero-
toxin C and the absence of the toxic shock syndrome toxin
appeared to be specific for the clonal isolates.
Nasal carriage and clinical characteristics. Among the pa-
tients for whom nasal swab specimens were available for cul-
ture, 79% showed nasal colonization by S. aureus during the
inclusion visit. When strain identity was assessed pairwise for
each of the patients at the time of presentation, 75% had the
same strain in the nose and the wound. Table 1 summarizes the
data obtained by statistical comparison of bacterial and clinical
characteristics. The presence of a given bacterial characteristic
was not related to sex, ethnicity, occurrence of lesions on the
head or the limbs, sensations of pain, frequency of impetigo,
preexisting eczema, or records of boils in the family (data not
shown). Table 1 highlights the characteristics that are statisti-
cally significant when the clinical signs and the presence or
absence of a given gene probed by BT are compared. All 111
strains derived from wounds for which both BT and toxin
detection results were available were included in the survey,
irrespective of their genotype (clone 8-related and genetically
heterogeneous strains). In order to circumvent clone 8-induced
bias, the same statistical exercise was repeated for the strains
harboring non-clone 8 genotypes. The boldface values in Table
1 highlight those parameters that retained significance upon
reanalysis. These will be discussed in more detail below.
A major marker for disease severity was the presence of the
bacterial ETB gene (Table 1). In particular, the number of
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lesions observed and the total surface size of the lesions were
highly significantly associated with the presence of ETB. Also,
positivity with BT probes BIN 1 (homologous to the Panton-
Valentine leukocidin gene) and BIN 4 (pSK41-like multiresis-
tance-encoding plasmid) seemed to be a predictor for the se-
verity of infection. Apparently, a strain harboring ETB and
sequences specific for the BIN 1 and BIN 4 probes showed
strong disease-inducing potential, probably due to the com-
bined presence of virulence and antibiotic resistance genes.
For ETB and BIN 1 this finding was corroborated by the
absence of lymphadenopathy. The association between car-
riage of the ETB-positive staphylococci and kindergarten at-
tendance disappeared upon elimination of clonal type 8 strains
from the analysis. Some additional conclusions can be drawn
from Table 1. The presence of the genes encoding enterotoxins
C and D predisposed individuals to pustule formation. Strains
harboring these genes did not seem to be spreading through
kindergarten-associated infections. Furthermore, different age
groups were colonized with different types of S. aureus isolates.
Finally, the sequence specific for the BIN 8 probe was associ-
ated with wound encrustation. Although the BIN 8 nucleotide
sequence corresponds to that of a gene in the S. aureus chro-
mosome to which a function has not yet been attributed and
that is ill defined at present, the observed association with
impetigo implies that additional research into the precise na-
ture of this potential virulence gene is warranted. BIN 2, whose
sequence matches that of another hypothetical gene, seems to
be associated with pustule formation. Again, further studies
into the nature of this gene are urgently required. Multivariate
analysis showed that the presence of the gene for ETB was the
clinically most relevant predictor of disease severity.
Relation between gene markers and clinical cure. None of
the univariate relationships between gene markers and clinical
cure after 1 week reached statistical significance, nor did nasal
staphylococcal carriage. In stepwise multivariate logistic re-
gression analysis, apart from treatment modality, only the pres-
ence of the BIN 4-specific sequence contributed significantly to
clinical cure (  	1.68; P  0.005), with a lower cure rate for
patients that were infected with BIN 4-specific sequence-pos-
itive strains. For bacterial cure after 1 week (data were avail-
able for 88 patients), the presence of ETB gene- and BIN
8-specific sequence-positive strains turned out to be statisti-
cally related. When the ETB gene was present, 40% of the
patients were cured after 1 week, whereas in the absence of the
gene, 60% were cured after 1 week (
2  5.25; degrees of
freedom  1; P  0.03). When strains were positive for the
BIN 8-specific sequence (which was the case for 84 of 88
children), 60% were cured within a week. Among the four
patients with a BIN 8-specific sequence-negative strain, none
were cured (
2  5.51; degrees of freedom  1; P  0.03). In
the regression analysis, apart from treatment modality, only
the BIN 7-specific sequence contributed to some extent, but
this was not statistically significant.
DISCUSSION
Nasal carriage of S. aureus is an important predisposing
factor for the development of staphylococcal infections (14).
The 79% carriage rate among our impetigo patients exceeds
the average carriage rates found in many other studies, sug-
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gesting that S. aureus carriage predisposes individuals to the
development of impetigo. However, the ultimate proof for this
should be based upon prospective studies, since our study
design does not enable a distinction between cause and effect.
On the basis of the present data set, it is not possible to
definitely conclude that nasal carriage precedes skin infection.
This would have required sequential bacterial cultivation prior
to impetigo development. This is an impracticable approach.
The toxin gene repertoire of a given S. aureus strain has been
suggested to be an important denominator for the strain’s
capacity to induce skin disease (3, 6, 17, 21). In particular, the
antigenically distinct subtypes of staphylococcal ETA and ETB
are putatively involved in the development of bullous impetigo.
Previous studies in Japan have demonstrated that approxi-
mately 70% of all clinical isolates produced either of these
toxins, whereas among strains isolated from patients with
atopic dermatitis and furuncles, these rates were 3 and 0%,
respectively (13). In Japan, ETA was present in 57 of 144
(40%) strains tested, ETB was present in 36 of 144 (25%)
strains, and both genes were present in 7 of 144 (5%) strains.
Our values were 12 of 98 (12%), 36 of 98 (37%), and 6 of 98
(6%) strains tested, respectively. This may suggest geographi-
cal differences in gene incidence, but it also suggests that both
ETA and ETB are important factors in the development and
progression of impetigo. The fact that ETB may be plasmid
borne probably contributes to its ease of dissemination (29).
Also, an association between exfoliative toxin gene content and
impetigo was documented in Italy (4, 5). It must be empha-
sized that the values mentioned above highlight the fact that
not all S. aureus strains causing impetigo harbor, for instance,
the ETB gene. This implies that additional factors, either host
or pathogen derived or both host and pathogen derived, affect
the development of impetigo. This suggests that impetigo is a
multifactorial syndrome, for which we provide evidence from
at least the bacteriological point of view.
We have shown here that, analogous to the already docu-
mented clinical importance of ETA in bullous impetigo, the
structurally similar toxin ETB contributes significantly to the
development of nonbullous impetigo. In particular, the surface
area and the number of impetigo lesions were increased in
patients with ETB-positive S. aureus infections. The epidemi-
ological association between the presence of the bacterial gene
and disease severity was very clear. Our study shows that clonal
dissemination of certain bacterial genotypes is important in
this respect, explaining a large proportion of disease cases.
Additional clinical-microbiological markers were identified by
BT. The sequence of one of these, BIN 4, displays homology to
the sequences of the VRS plasmids belonging to the pSK41
family (2, 9). How these multiresistance-encoding conjugative
plasmids, which harbor all requirements for gene transfer and
various insertion elements, relate to the severity of skin disease
is unclear at present. However, its apparent relatedness to a
delay of cure is probably due to the antibiotic resistance that is
associated with this class of plasmids. For another important
marker that we discovered, the sequence specific for BIN 1, the
relation to disease severity is more obvious: this binary probe
shares sequence homology with a Panton-Valentine leukocidin
located on prophage PV8 (12). The possible virulence effect
of such a molecule is obvious, as was also demonstrated in two
recent studies showing an increased incidence of the leukoci-
din gene among S. aureus strains isolated from impetigo pa-
tients (10) and general clinical isolates (11). Moreover, Lina et
al. (17) demonstrated that this leukocidin appears to be spe-
cifically associated with necrotic lesions of the skin and mucous
membranes.
In conclusion, we have shown here that impetigo among
patients living in a geographic region of limited size can be
caused by both clonally related and unrelated S. aureus strains.
For the first time, a relation between the virulence gene con-
tent and the severity of impetigo has been demonstrated. Most
particularly, we have demonstrated here that various virulence
factors are involved in impetigo and that the severity of disease
is probably dependent upon the combined presence and activ-
ities of these various factors. Independent of PFGE-defined
staphylococcal clonality, bacterial toxin and virulence gene
contents are important factors related to the severity and
sometimes even the course of the disease. Further improve-
ment of microbial gene typing strategies, such as those used in
the present study, may result in prospective therapeutic inter-
ventions guided by molecular assessment of the virulence of
the infectious agent.
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